In the last two decades, many European countries allowed the sale of over-the-counter (OTC) drugs outside pharmacies. This was expected to lower retail prices through increased competition. Evidence of such price reductions is scarce. We assess the impact of supermarket and outlet entry in the OTC drug market on OTC prices charged by incumbent pharmacies using a difference-in-differences strategy. We use price data on five popular OTC drugs for all retailers located in Lisbon for three distinct points in time (2006, 2010, and 2015). Our results suggest that competitive pressure in the market is mainly exerted by supermarkets, which charge, on average, 20% lower prices than pharmacies. The entry of a supermarket among the main competitors of an incumbent pharmacy is associated with an average 4% to 6% decrease in prices relative to the control group. These price reductions are long-lasting but fairly localized. We find no evidence of price reductions following OTC outlet entry. Additional results from a reduced-form entry model and a propensity score matching difference-in-differences approach support the view that these effects are causal.
Authors: Ana Moura, Pedro Pita Barros
You can find the research article here.
Eduardo Costa, PhD Candidate in Economics at Nova SBE, analyzed for Público whether the 100 million euros of the Health budget to hire 4200 professionals will be enough.Learn more
Opioid abuse is one of the biggest challenges currently faced by American society. Twenty-five years ago, Portugal too was amidst a drug epidemic. The Portuguese strategy to fight the drug epidemic had at its core the idea that drug addicts are not criminals, but rather patients who need help. And you know what? It succeeded.Learn more
Patient-reported outcome measures (PROMs) allow patients to report their health status before and after treatment and can be used to assess the quality of care. A number of countries collect PROMs from those with acute health problems and use this information in routine performance assessment. We address these challenges in our analysis of care delivered to patients with inflammatory chronic rheumatic disease in Portugal.Learn more